-+ 0.00%
-+ 0.00%
-+ 0.00%
Merck Sharp & Dohme's Diabetes Drug Steglatro Recommended for Extension of Indication
Share
Listen to the news
07:28 AM EST, 11/13/2026 (MT Newswires) -- Merck Sharp & Dohme's Steglatro for type 2 diabetes was recommended for a marketing authorization extension by the European Medicines Agency's Committee for Medicinal Products for Human Use, according to a Friday release. The US pharmaceutical company's Steglatro, which is already indicated for adults aged 18 years and above with type 2 diabetes mellitus, is now being recommended for the treatment of adults and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Steglatro may be used as monotherapy when metformin is considered inappropriate, or in addition to other treatments. The change to the existing marketing authorization remains subject to the European Commission's approval.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending